There are 1,197 papers on 25-hydroxyvitamin D in aging research: 356 trials and 642 observational studies in people, 13 in animals, 173 reviews. The newest story, Nov 13, 2026: “Low vitamin D linked to greater frailty in adults”.
Lower 25-hydroxyvitamin D is linked with higher mortality and incident frailty in human cohorts; levels are also associated with cognition and functional dependency in hospitalized older adults. Human trials report increased levels with vitamin D supplementation, including a calcifediol trial in vitamin D–deficient frail older adults.
587 findings in 432 papers from 1985 to 2026, 75 of them since April 2026
“the minor allele of a DBP SNP (rs7041) was positively associated with both 25OHD (B = 4.46, p = 1.97E-10)”
↑upin humans131↔no changein humans2↓downin humans1+45% to +98%
132 studies
Cholecalciferol increases 25-hydroxyvitamin D in humans (Adults with prediabetes receiving supplementation plus lifestyle advice) (18.4 ± 4.5 to 27.6 ± 2.8 ng/mL).
“Serum 25(OH) D rose from 18.4 ± 4.5 to 27.6 ± 2.8 ng/mL ( P < 0.001).”
Human trialAdults with prediabetes receiving supplementation plus lifestyle adviceserum2000 IU once daily3 monthsn = 45
Cholecalciferol increases 25-hydroxyvitamin D in humans (73.0 vs 99.7 vs 120.4 nmol/L).
“After 12 months, the concentrations were 73.0 ± 17.8, 99.7 ± 21.1 and 120.4 ± 21.8 nmol/L in the placebo, 1600 IU/day and 3200 IU/day arms, respectively (P < 0.001).”
Cholecalciferol increases 25-hydroxyvitamin D in humans (T-scores -1.5 to -2.5) (38.2 ± 7.5 ng/mL vs 28.5 ± 6.8 ng/mL).
“Mean serum 25(OH)D levels were substantially higher (p = 0.003) in the liposomal group (38.2 ± 7.5 ng/mL) than those in the control cholecalciferol group (28.5 ± 6.8 ng/mL).”
Human trialT-scores -1.5 to -2.5liposomal800 IU/day + 1000 mg calcium24 monthsfemalesn = 153
Vitamin D increases 25-hydroxyvitamin D in women with PCOS.
“The serum 25(OH)D concentrations at different time points after vitamin D supplementation were significantly higher than that in control group (P < 0.05).”
Human trialin women with PCOS2000 IU/day12 weeksfemalesn = 60
Vitamin D increases 25-hydroxyvitamin D in humans (patients with statin-associated muscle symptoms and vitamin D deficiency) (261% of baseline values).
“Blood vitamin D levels reached 261% of baseline values.”
Human trialpatients with statin-associated muscle symptoms and vitamin D deficiency6 months
Vitamin D increases 25-hydroxyvitamin D in humans.
“At the end of the study period 25(OH)D and 1,25(OH)2D levels increase and, PTH, VDBP levels decrease after vitamin D supplementation, yet, although LTL levels increase in both groups, the increase is more prominent in the placebo group.”
Vitamin D increases 25-hydroxyvitamin D in humans (from 13.4 ± 0.8 ng/mL to 29.6 ± 0.9 ng/mL).
“serum 25-hydroxyvitamin D [25(OH)D] level was 13.4 ± 0.8 ng / mL and it markedly increased to 29.6 ± 0.9 ng / mL after daily 1000-IU vitamin D-fortified milk intake for 6 months”
Ergocalciferol increases 25-hydroxyvitamin D in humans.
“At week 12, the mean 25(OH)D level was 96.7 ± 5.8 ng/mL in the vitamin D group and 23.8 ± 4.1 ng/mL in the control group (mean difference: 72.9; 95% confidence interval [CI]: 70.72 to 75.08; p < 0.001).”
Ergocalciferol increases 25-hydroxyvitamin D in humans (chronic intestinal failure and vitamin D deficiency) (96.7 ± 5.8 vs. 23.8 ± 4.1 ng/mL, p < 0.001).
“serum 25-hydroxyvitamin D levels were significantly higher in the vitamin D group than in the control group (96.7 ± 5.8 vs. 23.8 ± 4.1 ng/mL; p < 0.001).”
Human trialchronic intestinal failure and vitamin D deficiency600,000 units every two weeks10 weeksn = 84
Ergocalciferol increases 25-hydroxyvitamin D in humans.
“Following 6 months of weekly supplementation with 40,000 IU of vitamin D2, there was a statistically significant increase in the median serum 25(OH)D level.”
Ergocalciferol increases 25-hydroxyvitamin D in ESKD patients on dialysis (from 14.5 ± 7.3 to 27.2 ± 13.2 ng/mL, P < .001 and from 15.1 ± 6.4 to 28.8 ± 11.5 ng/mL, P < .001).
“the average serum 25-hydroxyvitamin D levels in the severity-dependent and fixed-dose groups were significantly elevated”
Human trialin ESKD patients on dialysis6 monthsn = 76
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·
Ergocalciferol increases 25-hydroxyvitamin D in humans (early postmenopausal women with vitamin D deficiency) (70% achieved >30 ng/ml; p < 0.05).
“70% of women in group I achieved a sufficient level of serum 25(OH)D (>30 ng/ml). There were significant differences in changes of serum 25(OH)D levels between the two groups (p < 0.05)”
Human trialearly postmenopausal women with vitamin D deficiency40 000 IU/week12 weeksfemalesn = 88
Calcifediol increases 25-hydroxyvitamin D in humans (hypovitaminosis D).
“Calcifediol and weekly cholecalciferol induced a greater and faster increase of serum 25(OH)D, compared to monthly or single-dose cholecalciferol administration.”
Calcifediol increases 25-hydroxyvitamin D in humans (vitamin D deficient frail older adults) (87.3 ± 20.6 nmol/L vs 43.8 ± 14.1 nmol/L placebo).
“Blood 25-hydroxycholecalciferol levels were significantly higher after calcifediol supplementation (87.3 ± 20.6 nmol/L) than after placebo (43.8 ± 14.1 nmol/L).”
Human trialvitamin D deficient frail older adults10 μg per day6 months
Cholecalciferol + calcium increases 25-hydroxyvitamin D in humans (asymptomatic hypovitaminosis D and low TBS) (29.1 ± 11.7 to 63.2 ± 22.2 nmol/L at 12-months).
“Mean serum 25(OH)D (nmol/L) showed a significant rise following supplementation (29.1 ± 11.7 at baseline to 68.8 ± 47.4 and 63.2 ± 22.2 at 6- and 12-months, respectively).”
Human trialasymptomatic hypovitaminosis D and low TBS1 yearn = 50
Vitamin D + magnesium increases 25-hydroxyvitamin D in humans (difference = 5.63; CI, -10.0 to -1.21; P = .001).
“significant increase in serum 25-hydroxyvitamin D concentrations in the vitamin D and magnesium group compared with the placebo group (difference = 5.63; CI, -10.0 to -1.21; P = .001)”
Metformin increases 25-hydroxyvitamin D in DMT2 patients on metformin alone, during vitamin D3 supplementation (+62.6% at 6 months and +50.6% at 12 months versus baseline).
“The metformin group showed the highest change in circulating vitamin D levels both at 6 months (62.6%) and 12 months (50.6%) as compared to baseline (p < 0.001).”
Human trialin DMT2 patients on metformin alone, during vitamin D3 supplementation2000 IU daily vitamin D312 monthsn = 121
Whey protein + vitamin D increases 25-hydroxyvitamin D in humans (4.6 (2.2, 7.1) ng/ml).
“the estimated mean (95% confidence interval; (CI)) difference in six-month change attributable to the nutritional intervention, controlling for sex and site, was 4.6 (2.2, 7.1) ng/ml”
Purified cytoplasm of pollen + vitamin D + vitamin K2
↑upin humans1
1 study
Purified cytoplasm of pollen + vitamin D + vitamin K2 increases 25-hydroxyvitamin D in humans.
“Statistically significant differences were found for 25OHD between T0 and T3 in Group A, showing a +63.0% increase (p = 0.0004) and in the comparison between Group A and Group B at T3 (p = 0.0002), as shown in.”
25-hydroxyvitamin D was not clearly linked with mortality in participants with albumin <40 g/L.
“In the group with a lower albumin level (<40 g/L), the associations failed to reach statistical significance in all participants as well as in women and in men.”
Mayo Clinic proceedings. Innovations, quality & outcomes·
25-hydroxyvitamin D is linked with lower bone mineral density in humans (sunny season constant S-25OHD<40 nmol/L vs >70 nmol/L) (10.0% (95% CI,3.8%-16.1%) lower).
“women with sunny season constant S-25OHD<40 nmol/L displayed 10.0% (95% CI,3.8%-16.1%) lower total hip BMD at follow-up.”
Humanssunny season constant S-25OHD<40 nmol/L vs >70 nmol/Ltotal hip12 yearsfemalesn = 1,802
25-hydroxyvitamin D improves muscle strength in humans (maintenance of optimal serum levels).
“maintaining optimal serum levels of 25-hydroxyvitamin D is crucial for optimizing bone tissue mineralization, restoring the strength and proprioception of periarticular skeletal muscles”
Reviewmaintenance of optimal serum levelsperiarticular skeletal muscle
25-hydroxyvitamin D was not clearly linked with hospital length of stay in humans (Hospitalized adults with delirium; per 10-ng/mL increase in serum 25-hydroxyvitamin D) (Adjusted median difference −0.81 days per 10-ng/mL increase, 95% CI −2.18 to 0.56; p = 0.250).
“Adjusted median length of stay was also not associated with serum 25(OH)D”
HumansHospitalized adults with delirium; per 10-ng/mL increase in serum 25-hydroxyvitamin Dn = 184
25-hydroxyvitamin D is linked with cognitive function in humans (Statistical mediation of the association between oxidative balance score and cognition) (Indirect effect a × b = −0.025).
“The indirect effect of OBS on cognition through 25(OH)D was significant ( a × b = –0·025).”
HumansStatistical mediation of the association between oxidative balance score and cognitionn = 1,891
25-hydroxyvitamin D impairs sleep quality in humans (vitamin D supplementation during weight loss).
“a greater magnitude of change in serum 25(OH)D was associated with an increased need to take medications to sleep (ptrend=0.01) and overall worse sleep quality (ptrend<0.01).”
Human trialvitamin D supplementation during weight loss12 monthsfemales
Male sex is linked with lower 25-hydroxyvitamin D in humans during the year after a hip fracture (15.2 ng/mL vs 23.9 ng/mL, p < 0.001).
“median 25OHD levels were 15.2 ng/mL (IQR 10.0) in men compared with 23.9 ng/mL (IQR 13.4) in women and remained lower in men at 2, 6, and 12 months (all p < 0.001).”
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
Parkinson's disease
↔no changein humans1
1 study
Parkinson's disease was not clearly linked with 25-hydroxyvitamin D in humans (Reverse Mendelian randomization).
“The reverse MR analysis indicated insufficient evidence of PD causing decreased vitamin D levels (P = 0.776).”
Parathyroid hormone is linked with 25-hydroxyvitamin D in humans (50.48% mediated).
“Estimates of the mediation ratio indicated that increased PTH mediated a 50.48% negative correlation between PM2.5 exposure and circulating 25(OH)D level.”
HumansMediation of the association between fine particulate matter exposure and circulating 25-hydroxyvitamin Dserumn = 13,194
25-hydroxyvitamin D is associated with mortality in humans (CKM syndrome stages 0–3; serum 25-hydroxyvitamin D above versus below 52.20 nmol/L) (2% lower risk; HR 0.98, 95% CI 0.97–0.99).
25-hydroxyvitamin D is associated with mortality in humans (Postmenopausal women; multivariate-adjusted analysis) (L-shaped relationship; cut-off 73.89 nmol/L).
“After multivariate adjustment, higher serum 25(OH)D levels were significantly related with lower all-cause and CVD mortality.”
Frailty is associated with 25-hydroxyvitamin D in humans (coronary artery disease before elective percutaneous coronary intervention) (20.02 ± 7.36 (17.53–22.51) ng/mL vs. 23.91 ± 8.92 (21.02–26.81) ng/mL, р = 0.044).
“Frailty in patients with CAD was associated with significantly lower serum total vitamin D (25-OH) levels compared to non-frail patients”
Humanscoronary artery disease before elective percutaneous coronary interventionserumn = 174
25-hydroxyvitamin D is associated with frailty in humans (OR 2.45, 95% CI: 1.38 to 4.35).
“Participants with the lowest quartile of plasma 25(OH) D were more likely to be frail (odds ratio [OR] 2.45, 95% confidence interval [CI]: 1.38 to 4.35) than those in the highest quartile.”
25-hydroxyvitamin D is linked with a lower risk of frailty in humans (adjusted for age, body mass index, center, and baseline frailty) (OR 0.84 (0.75, 0.95)).
“25OHD: 0.84 (0.75, 0.95); -4.4%, (-6.7, -2.0)”
Humansadjusted for age, body mass index, center, and baseline frailty4.3 yearsmalesn = 2,114
25-hydroxyvitamin D is associated with dementia in humans (Serum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographics) (HR 0.58, 95% CI 0.49–0.69).
“serum 25(OH)D concentrations were inversely associated with the risk of dementia, MCI, and delirium in a dose-dependent manner after adjusting for demographics”
HumansSerum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographicsserumn = 443,427
25-hydroxyvitamin D is associated with bone mineral density in humans (Crohn's disease; vitamin D supplementation; normal versus low serum 25-hydroxyvitamin D) (Bone mineral density increases in 68% with normal serum concentrations versus 18% with low concentrations; P = 0.008).
“Increases in bone mineral density were especially prevalent among patients who received the supplement and had normal serum levels of 25-hydroxyvitamin D (68%)”
Human trialCrohn's disease; vitamin D supplementation; normal versus low serum 25-hydroxyvitamin Ddistal nondominant forearm1000 IU/day vitamin D1 year
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
25-hydroxyvitamin D is associated with bone mineral density in humans (p = 0.001).
“Serum concentrations of 25(OH)D were significantly and positively associated with BMD total hip (p = 0.001)”
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·
25-hydroxyvitamin D is associated with bone mineral density in humans (p = 0.01).
“Higher femoral neck BMD was observed in men with higher baseline vitamin D status, after adjustment for age, season, BMI, smoker status, alcohol consumption, physical activity and social class (p = 0.01).”
Humansadjusted for age, season, BMI, smoker status, alcohol consumption, physical activity and social classbonemales
25-hydroxyvitamin D is associated with sarcopenia in humans (sarcopenic participants compared with controls, random-effects meta-analysis) (SMD 1.163 (95% CI 0.514, 1.812); I2=99.652%).
“Sarcopenic participants had significantly lower serum levels of 25(OH)D (SD =1.163; 95% CI 0.514, 1.812; p<0.001; I2=99.652%)”
Humanssarcopenic participants compared with controls, random-effects meta-analysisn = 19,528
25-hydroxyvitamin D is associated with osteoporosis in humans (p = 0.001).
“In multiple linear regression analysis, age and osteoporosis diagnosis remained negatively associated with 25(OH)D levels (p = 0.021 and p = 0.001, respectively)”
25-hydroxyvitamin D is associated with bone mineral density in humans (baseline, before supplementation).
“Baseline total and free 25(OH)D concentrations were positively associated with 1,25(OH)2D, 24,25(OH)2D (p < 0.001), vitamin D binding protein (DBP) (p < 0.05), BMD, and BMC (p < 0.05).”
Human trialbaseline, before supplementationbonen = 379
25-hydroxyvitamin D is associated with body mass index in humans (25(OH)D > 35 ng/mL compared with < 12 ng/mL; bariatric surgery candidates) (1.81 kg/m2 lower BMI; 3.30 cm lower WC).
“Compared with 25(OH)D < 12 ng/mL, concentrations > 35 ng/mL were associated with 1.81 kg/m2 lower BMI”
Humans25(OH)D > 35 ng/mL compared with < 12 ng/mL; bariatric surgery candidatesn = 4,822
25-hydroxyvitamin D is associated with body mass index in humans (β = –1.02 (95% CI –1.46 to –0.58) and β = –1.29 (95% CI –1.77 to –0.80), respectively; both p < 0.0001).
“Higher baseline vitamin D levels are independently associated with enhanced glycemic and weight loss responses to semaglutide in individuals with T2D.”
HumansType 2 diabetes treated with semaglutide; baseline 25(OH)D 15–24.9 or ≥25 ng/mL versus <15 ng/mL12 monthsn = 5,300
25-hydroxyvitamin D is associated with type 2 diabetes in humans (seasonally normalized 25(OH)D deficiency).
“Associations previously observed in LHS and TriNetX were reproduced, notably for diabetes, myocardial infarction, cerebrovascular disease, dementia, diabetic retinopathy, and end-stage renal disease”
25-hydroxyvitamin D is associated with mild cognitive impairment in humans (Serum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographics) (HR 0.55, 95% CI 0.37–0.84).
“serum 25(OH)D concentrations were inversely associated with the risk of dementia, MCI, and delirium in a dose-dependent manner after adjusting for demographics”
HumansSerum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographicsserumn = 443,427
GC is associated with 25-hydroxyvitamin D in humans (treatment with low dose vitamin D (2000 IU)).
“We found that rs7041 (located on chromosome 4, GC) was significantly associated with response to vitamin D treatment with low dose vitamin D (2000 IU) at 6 and 12 months (permuted p values 0.001 and 0.023 respectively).”
Human trialtreatment with low dose vitamin D (2000 IU)one year
Diabetic medicine : a journal of the British Diabetic Association·
25-hydroxyvitamin D is associated with HbA1c in humans (β = –0.083 (95% CI –0.154 to –0.013), p = 0.020; β = –0.096 (reported 95% CI –0.017 to –0.017), p = 0.016, respectively).
“Higher baseline vitamin D levels are independently associated with enhanced glycemic and weight loss responses to semaglutide in individuals with T2D.”
HumansType 2 diabetes treated with semaglutide; baseline 25(OH)D 15–24.9 or ≥25 ng/mL versus <15 ng/mL12 monthsn = 5,300
International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition·
VDR is associated with 25-hydroxyvitamin D in humans (Chinese women; Cdx-2 promoter polymorphism).
“In women, the association of Cdx-2 polymorphism with serum 25(OH)D levels was significant”
Lower 25-hydroxyvitamin D is linked with higher mortality in human cohorts; higher levels are associated with lower odds of dementia in hospitalized older adults and lower fragility fracture risk in patients undergoing maintenance hemodialysis. Human trials report that cholecalciferol raises its levels; calcifediol does so in vitamin D–deficient frail older adults.
Human observational studies link lower 25-hydroxyvitamin D with higher mortality, and higher levels with lower dementia odds in hospitalized older adults and lower fragility-fracture risk in people receiving maintenance hemodialysis. Human trials report increased levels with cholecalciferol; a calcifediol trial also reports increases in vitamin D-deficient frail older adults.
Lower 25-hydroxyvitamin D is associated with higher mortality and, in men, frailty in human observational studies. Bone associations differ: higher levels accompany higher hip bone density T-scores in men but lower femur T-scores in heart transplant recipients. Human trials report that cholecalciferol and ergocalciferol raise levels.
Summary rewritten as its findings changed.
As it read before
A human trial shows cholecalciferol increases 25-hydroxyvitamin D. Human studies associate this biomarker with lower cancer mortality, cardiometabolic risk clustering and physical function after osteoporotic fragility fractures, while one study finds no association with colorectal neoplasms in Lynch syndrome carriers.
Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.